{"brief_title": "ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Na\u00efve HIV-Infected Subjects", "brief_summary": "To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["Lopinavir/Ritonavir", "Lamivudine", "Stavudine"], "description": ["Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs", "150 mg, every 12 hours", "40 mg every 12 hours"], "arm_group_label": ["1", "2", "1", "2", "1", "2"], "other_name": ["ABT-387", "Kaletra"], "criteria": "Inclusion Criteria - HIV-1 positive - antiretroviral-adult males - non-pregnant - non-lactating females at least 18-years old with plasma HIV-1 RNA > 5000 copies/mL, who were not acutely ill Exclusion Criteria - History of: - prior antiretroviral therapy - significant drug hypersensitivity - psychiatric illness that precludes compliance - an active substance abuser - positive test results for drug abuse - abnormal lab test results (hemoglobin, absolute neutrophil count, platelet count, SGPT/AST or SGPT/ALT, creatinine, fasting triglycerides, significant abnormal ECG results - pregnancy or lactating female - received another investigational drug within 28 days of study initiation - unlikely to comply or unsuitable candidate in the opinion of the investigator", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Reverse Transcriptase Inhibitors", "mesh_term": ["HIV Infections", "Ritonavir", "Lopinavir", "Stavudine", "Lamivudine", "Reverse Transcriptase Inhibitors"], "id": "NCT00004578"}